AMI-1

CAT:
804-HY-18962-01
Size:
10 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
AMI-1 - image 1

AMI-1

  • UNSPSC Description:

    AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding[1].
  • Target Antigen:

    Histone Methyltransferase
  • Type:

    Reference compound
  • Related Pathways:

    Epigenetics
  • Applications:

    Cancer-programmed cell death
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/AMI-1.html
  • Purity:

    98.0
  • Solubility:

    H2O : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
  • Smiles:

    O=C(NC1=CC2=CC(S(=O)(O[Na])=O)=CC(O)=C2C=C1)NC3=CC4=CC(S(=O)(O[Na])=O)=CC(O)=C4C=C3
  • Molecular Weight:

    548.45
  • References & Citations:

    [1]Zhang, B., et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep 8;6(26):22799-811.|[2]Baolai Zhang, et al. Arginine Methyltransferase inhibitor-1 Inhibits Sarcoma Viability in vitro and in vivo. Oncol Lett. 2018 Aug;16(2):2161-2166.|[3]Donghang Cheng, et al. Small Molecule Regulators of Protein Arginine Methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9.Cell Death Dis. 2023 Sep 22;14(9):624.|Genes Dis. 2023 Mar 28.|Nat Commun. 2023 Feb 23;14(1):1011.|Cell Rep. 2024 Aug 22;43(9):114662.|Cell Rep. 2024 Jul 24;43(8):114537.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, sealed storage, away from moisture)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    20324-87-2